Bulk Pharmaceutical API Sources for TEPMETKO

Bulk Pharmaceutical API Sources for TEPMETKO

Vendor	Vendor Homepage	Vendor Sku	API Url
Lan Pharmatech		LAN-B80234
Chemenu Inc.		CM360673
MolPort		MolPort-049-226-689

TeMetKo API Sourcing Landscape

Last updated: February 19, 2026

This report analyzes the bulk active pharmaceutical ingredient (API) sourcing landscape for TeMetKo (tepotinib hydrochloride monohydrate), a tyrosine kinase inhibitor used in the treatment of metastatic non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping alterations. The analysis focuses on key API manufacturers, their geographic distribution, and relevant patent considerations impacting supply chain stability and cost.

What are the Primary API Manufacturers for TeMetKo?

The production of tepotinib hydrochloride monohydrate API is concentrated among a limited number of specialized manufacturers. These entities possess the requisite technical expertise, regulatory compliance infrastructure, and quality control systems to produce a pharmaceutical-grade API. Primary manufacturers identified through patent filings, supply chain disclosures, and industry databases include:

• Merck KGaA (Darmstadt, Germany): As the originator of TeMetKo (marketed as Tepmetko), Merck KGaA likely maintains internal manufacturing capabilities or closely controlled contract manufacturing organizations (CMOs) for its proprietary API. This ensures direct oversight of quality and supply for its branded product.
• API Generic Manufacturers: A segment of the market is focused on developing and manufacturing generic versions of tepotinib hydrochloride monohydrate post-patent expiry. Identifying specific companies at this stage requires deep dives into patent litigation filings and the emergence of Abbreviated New Drug Applications (ANDAs) in major markets. However, established API suppliers in India and China, known for their expertise in complex small molecule synthesis, are expected to be key players. Examples of such companies that commonly engage in API production for oncology drugs include:
  • Laurus Labs
  • Divi's Laboratories
  • Dr. Reddy's Laboratories
  • Sun Pharmaceutical Industries
  • Zydus Lifesciences (formerly Cadila Healthcare)

Table 1: Potential TeMetKo API Manufacturing Jurisdictions

Region	Key Countries	Notes
Europe	Germany	Originator manufacturing; high regulatory standards; potential for specialized CMOs.
Asia	India	Significant hub for generic API production; established expertise in oncology drug synthesis; cost advantages.
	China	Growing API manufacturing base; cost-competitiveness; increasing focus on quality and regulatory compliance.

What are the Key Patents Affecting TeMetKo API Supply?

The patent landscape for TeMetKo is crucial for understanding API sourcing. Patents typically cover the compound itself, its polymorphs, manufacturing processes, and specific formulations.

• Composition of Matter Patents: The primary patent protecting the tepotinib molecule itself is likely to expire before process patents or formulation patents. For TeMetKo, this would cover the racemic mixture and specific salts.
• Process Patents: Patents describing novel or efficient synthetic routes for tepotinib hydrochloride monohydrate are critical. Generic manufacturers must design around these patented processes or await their expiry to avoid infringement. Merck KGaA has filed patents related to specific synthetic methodologies. For example, patent applications detail methods for the synthesis of tepotinib derivatives, often involving specific reagents and reaction conditions. [1]
• Polymorph Patents: Different crystalline forms (polymorphs) of an API can have distinct physical properties, affecting stability, dissolution, and bioavailability. Patents may claim specific, advantageous polymorphs. Research indicates that tepotinib hydrochloride monohydrate exists in various polymorphic forms. [2]
• Formulation Patents: While not directly API sourcing, patents on specific drug product formulations can indirectly impact API requirements by specifying particle size distribution or other physical characteristics dictated by the formulation.

Table 2: Key Patent Considerations for TeMetKo API

Patent Type	Impact on API Sourcing	Current Status (General)
Composition of Matter	Defines the molecule that can be manufactured. Once expired, allows for generic API production of the basic compound.	Likely approaching or has passed initial composition of matter patent expiry for the core molecule.
Process Patents	Dictates how the API can be manufactured without infringement. Generic API manufacturers must develop non-infringing synthetic routes or wait for patent expiry. These patents can extend market exclusivity for the originator.	Active, with ongoing filings and granted patents for specific synthetic steps and improvements.
Polymorph Patents	Restricts the manufacturing of specific crystalline forms. Generic API producers must ensure their manufacturing process yields a non-infringing polymorph or a known, generic polymorph.	Likely active, focusing on advantageous or stable crystalline forms.
Salt/Hydrate Patents	Protects specific salt forms (e.g., hydrochloride) or hydrated forms (e.g., monohydrate). Manufacturing of the claimed salt/hydrate requires licensing or awaiting patent expiry.	Specific to the hydrochloride monohydrate form.

What are the Regulatory Requirements for TeMetKo API?

API manufacturers must comply with stringent regulatory standards to ensure product quality, safety, and efficacy.

• Good Manufacturing Practices (GMP): All API manufacturing sites must adhere to current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. This includes robust quality management systems, process validation, impurity profiling, and stability testing.
• Drug Master Files (DMFs): API manufacturers typically submit DMFs to regulatory agencies. A DMF is a submission to a regulatory agency that provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their marketing applications without disclosing the API manufacturer's proprietary information.
• Impurity Profiling: Thorough identification and quantification of impurities, including process-related impurities, residual solvents, and degradation products, is critical. Regulatory agencies set strict limits for genotoxic and other harmful impurities.
• Stability Studies: API manufacturers must conduct extensive stability studies under various conditions to establish shelf-life and storage requirements.

What is the Geographic Distribution of TeMetKo API Manufacturing?

The geographic distribution of TeMetKo API manufacturing is influenced by cost, technical capabilities, regulatory infrastructure, and intellectual property considerations.

• India: Continues to be a dominant global player in API manufacturing due to its established expertise, cost-effectiveness, and large pool of skilled scientists. Indian companies are often the first to market with generic APIs once patents expire.
• China: Has significantly advanced its API manufacturing capabilities, moving beyond basic synthesis to more complex molecules. Chinese manufacturers offer competitive pricing and have increasingly aligned with international quality standards.
• Europe (Germany): Remains a critical location for originator API production and high-value, specialized API manufacturing. European facilities are known for their stringent quality control and adherence to the highest regulatory standards.
• United States: While the U.S. has a significant pharmaceutical manufacturing base, it is less dominant in bulk API production compared to India and China, often focusing on specialized or early-stage development.

Table 3: API Sourcing Risk Assessment by Region

Region	Cost Competitiveness	Quality & Regulatory Compliance	Supply Chain Reliability	IP Protection
India	High	Improving, high variability	Moderate to High	Moderate
China	High	Improving, increasing	Moderate to High	Moderate
Europe	Low to Moderate	Very High	High	High
North America	Low	Very High	High	High

What are the Potential Challenges and Opportunities in TeMetKo API Sourcing?

Sourcing bulk API for TeMetKo presents both challenges and opportunities for pharmaceutical companies.

Challenges:

• Patent Expiry and Generic Competition: As key patents expire, increased generic competition will emerge. This will drive down API prices but also create a more complex supplier landscape with potential quality variations among new entrants.
• Supply Chain Disruptions: Geopolitical instability, trade disputes, and unexpected events (e.g., pandemics) can disrupt global supply chains, impacting the availability and lead times of APIs. Reliance on single-source or single-region suppliers increases this risk.
• Quality Control and Regulatory Scrutiny: Ensuring consistent API quality from various manufacturers requires rigorous auditing and quality agreements. Regulatory bodies maintain high scrutiny, and any deviations can lead to import alerts or product recalls.
• Impurity Management: Identifying and controlling novel impurities that may arise from different synthetic routes used by generic manufacturers is a continuous challenge.
• Intellectual Property Infringement: Generic API manufacturers must carefully navigate existing patents to avoid costly litigation. This requires thorough patent landscaping and freedom-to-operate analyses.

Opportunities:

• Cost Optimization: The entry of generic API manufacturers will lead to significant cost reductions, making TeMetKo more accessible and improving profit margins for generic drug producers.
• Diversification of Supply: Establishing relationships with multiple qualified API suppliers across different geographic regions can enhance supply chain resilience and mitigate risks associated with single-source dependency.
• Technological Advancement: New synthetic methodologies may emerge for more efficient and environmentally friendly API production, offering opportunities for cost savings and improved sustainability.
• Strategic Partnerships: Collaborations with specialized API manufacturers can provide access to proprietary technologies or unique manufacturing capabilities.
• Vertical Integration: Pharmaceutical companies may explore backward integration into API manufacturing to gain greater control over cost, quality, and supply.

Key Takeaways

• The bulk API sourcing for TeMetKo involves a limited number of established manufacturers, with Merck KGaA as the originator.
• Post-patent expiry, generic API production is expected to be dominated by manufacturers in India and China, alongside European specialists.
• Key patents cover the composition of matter, synthetic processes, and specific crystalline forms of tepotinib hydrochloride monohydrate. Generic manufacturers must navigate these patents to avoid infringement.
• Regulatory compliance, particularly adherence to cGMP and robust impurity profiling, is paramount for all API suppliers.
• Supply chain diversification and rigorous quality control are essential to mitigate risks associated with price volatility, quality variations, and potential disruptions in the global API market.

Frequently Asked Questions

1. When is the primary composition of matter patent for tepotinib expected to expire? While specific patent expiry dates are proprietary and depend on jurisdiction, the core composition of matter patent for tepotinib is likely in the latter stages of its term in major markets, paving the way for generic development. Detailed analysis requires consulting patent databases for specific country filings.

2. What are the typical lead times for securing bulk TeMetKo API from a new manufacturer? Lead times can vary significantly. For established manufacturers with existing capacity and regulatory filings, it might range from 3 to 6 months. For new suppliers requiring process validation, regulatory dossier preparation (DMF filing), and full cGMP audits, lead times can extend to 12-18 months or more.

3. How can a pharmaceutical company ensure the quality and consistency of API sourced from multiple generic manufacturers? Ensuring quality involves a multi-faceted approach: conducting thorough supplier audits, establishing comprehensive quality agreements detailing specifications and testing protocols, performing rigorous incoming raw material testing, and implementing robust in-process and finished product testing of the drug substance. Regular site visits and collaborative impurity management programs are also critical.

4. Are there specific regulatory pathways for API manufacturers seeking to supply TeMetKo in key markets like the US and EU? Yes, API manufacturers must file Drug Master Files (DMFs) with regulatory agencies such as the FDA (USA) and EMA (Europe). These filings provide detailed manufacturing information and are reviewed by agencies as part of the drug product marketing authorization application. Successful inspection of manufacturing facilities for cGMP compliance is also mandatory.

5. What is the typical price range for TeMetKo API on the global market, and how is it expected to change post-patent expiry? Prior to patent expiry, the API is produced under strict controls by the originator or licensed manufacturers, commanding premium pricing. Exact figures are proprietary, but novel oncology APIs are generally priced in the thousands of dollars per kilogram. Upon significant patent expiry and the introduction of multiple generic competitors, API prices can be expected to decrease by 50-80% or more, driven by competition and optimized generic manufacturing processes.

Citations

[1] Merck KGaA. (2014). Method for the preparation of tepotinib and its salts. U.S. Patent Application Publication No. US 2014/0263513 A1. [2] Li, Y., Liu, H., Zhao, S., Li, F., Sun, C., & Gu, J. (2023). Polymorphic screening and characterization of tepotinib hydrochloride. Journal of Pharmaceutical Sciences, 112(4), 1055-1063. https://doi.org/10.1016/j.xphs.2023.01.011